Trial reportThe Journal of infectious diseases2026
The Effect of Pertussis Vaccination During Pregnancy on the Binding Epitopes and Avidity of Anti-Pertussis Toxin Immunoglobulin G Antibodies in Infants and Their Mothers.
Trial report in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunization during pregnancy (IP) against pertussis protects young infants, but the maternally derived antibodies blunt the quantity of infants' antibody responses to their primary vaccination. While the blunting effect has been well studied for antibody quantity, potential blunting that would affect functional characteristics of these antibodies is less studied. This study evaluated the effect of IP on the epitopes and avidity of anti-pertussis toxin (PT) immunoglobulin G (IgG) antibodies in infants and their mothers.
methodsIn this prospective open-label controlled clinical trial, 47 pregnant women received diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine booster, and 22 pregnant women who were not vaccinated served as controls. Sixty-nine infants received hexavalent DTaP vaccine at 3 and 5 months of age. The binding strength of anti-PT IgG antibodies and their ability to inhibit epitope-specific binding of mouse monoclonal antibodies were measured with enzyme-linked immunosorbent assays in both maternal and infant samples.
resultsIn both study groups, antibodies in cord blood showed higher epitope-specific inhibition and avidity than what was induced in infants after 2 primary vaccine doses, at age 6 months. Higher anti-PT IgG concentrations (P < .001) and epitope-specific inhibition targeting 1B7 (P = .049) and 11E6 (P = .02) were noted at age 6 months in control group infants, suggesting epitope-specific blunting in the IP group. No difference was observed in the avidity of anti-PT IgG at age 6 months between 2 study groups. The increase in avidity after vaccination was the highest in those mothers and infants with lower baseline avidity.
conclusionsIP decreased primary vaccination-induced antibody responses disproportionately against different PT epitopes in infants. CLINICAL TRIALS REGISTRATION: European Union Clinical Trial database (EudraCT no. 2019-001986-34; https://www.clinicaltrialsregister.eu).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.